Abstract
A 76-year-old woman with primary biliary cirrhosis and hypertension had been treated with a combination of oral ursodeoxycholic acid, bezafibrate and benidipine hydrochloride. After switching from brand name to generic bezafibrate, her liver injury became exacerbated. Her lymphocytes reacted with generic bezafibrate on a drug-lymphocyte stimulation test (DLST), indicating that her liver injury was likely caused by the switch to generic bezafibrate. Treatment with this agent was stopped, improving her liver function. These findings indicate that all forms of bezafibrate are not equal, that this generic formulation caused liver injury to this patient, and that DLST was useful diagnostically.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
